PineBridge Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

PineBridge Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.9M	Sell	195,709 -75,710	-28%	-$22.8M	0.49%	46
2026 Q1	$89.8M	Buy	271,419 +171,220	+171%	+$58.3M	0.76%	27
2025 Q4	$39.8M	Buy	100,199 +99,542	+15,151%	+$44.1M	0.29%	67
2025 Q3	$300K	Buy	+657	New	+$268K	﹤0.01%	516
2024 Q4	–	Sell	-8,222	Closed	-$2.26M	–	710
2024 Q3	$2.26M	Sell	8,222 -688	-8%	-$179K	0.02%	440
2024 Q2	$2.17M	Sell	8,910 -4,442	-33%	-$701K	0.02%	377
2024 Q1	$1.99M	Buy	13,352 +3,171	+31%	+$529K	0.02%	413
2023 Q4	$1.95M	Buy	10,181 +2,805	+38%	+$478K	0.02%	376
2023 Q3	$1.31M	Buy	+7,376	New	+$1.41M	0.01%	416

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PineBridge Investments's ALNY Position: Q2 2026 in Review

PineBridge Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 28% in Q2 2026, selling an estimated $22.8M and leaving 195,709 shares worth $58.9M. The position accounts for 0.49% of the portfolio, ranked #46.

PineBridge Investments first reported a position in ALNY in Q3 2023 and has held it in 9 quarters since. The position peaked at $89.8M in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

PineBridge Investments held 195,709 shares of Alnylam Pharmaceuticals worth $58.9M as of Q2 2026.
PineBridge Investments sold 75,710 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $22.8M.
Alnylam Pharmaceuticals made up 0.49% of PineBridge Investments's portfolio in Q2 2026, its #46 holding.
PineBridge Investments first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
PineBridge Investments's Alnylam Pharmaceuticals position peaked at $89.8M in Q1 2026.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on PineBridge Investments's 13F filing for Q2 2026, filed 14 Aug 2026.